Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | Treatment strategies for high-risk MM

Jesús San Miguel • 7 May 2020
COMy Virtual 2020
Multiple Myeloma Alnuctamab Antibodies Bortezomib CAR-T Carfilzomib Daratumumab Isatuximab Lenalidomide Melphalan

Jesus San Miguel, MD, Universidad de Navarra, Navarra, discusses treatment strategies for high-risk multiple myeloma patients, including immunotherapeutic options, such as monoclonal antibodies, bispecific antibodies and CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jesús San Miguel

PRO and safety in patients with NDMM achieving MRD negativity in the PERSEUS and CEPHEUS trials 4:12
PRO and safety in patients with NDMM achieving MRD negativity in the PERSEUS and CEPHEUS trials
Jesús San Miguel • 9 Sep 2025
Updated findings from GEM2017FIT: triplet versus quadruplet regimen in NDMM 4:56
Updated findings from GEM2017FIT: triplet versus quadruplet regimen in NDMM
Jesús San Miguel • 9 Sep 2025
Approaching patients with myeloma who progress on lenalidomide & daratumumab: challenges 2:04
Approaching patients with myeloma who progress on lenalidomide & daratumumab: challenges
Jesús San Miguel • 19 Sep 2024
CARTITUDE-4: how is CAR-T opening new avenues for the treatment of R/R myeloma? 1:28
CARTITUDE-4: how is CAR-T opening new avenues for the treatment of R/R myeloma?
Jesús San Miguel • 19 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals